Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human study of GSK2881078
NCT02045940Phase 1Completed
- Sponsor
- GSK
- Start
- Jan 2014
- Primary completion
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GSK2881078 in cachexia (5 cohorts), sponsored by GSK. Primary endpoints: Vital sign assessment following single doses up to 61 days, Vital sign assessment following repeat doses up to 56 days and 8 more. Started Jan 2014; status: completed.
02
Drugs
GSK2881078
03
Conditions
cachexia
Beyond the preview
Go deeper on NCT02045940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02045940.